中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
20期
54-55
,共2页
紫杉醇%奈达铂%顺铂%同步放化疗%局部晚期非小细胞肺癌
紫杉醇%奈達鉑%順鉑%同步放化療%跼部晚期非小細胞肺癌
자삼순%내체박%순박%동보방화료%국부만기비소세포폐암
Paclitaxel%Nedaplatin%Cisplatin%Concurrent chemoradiotherapy%Locally advanced non-small cell lung cancer
目的?观察每周小剂量紫杉醇联合奈达铂或顺铂同步放化疗治疗局部晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法?58例不能手术Ⅲ期非小细胞肺癌患者(Ⅲa期22例,Ⅲb期36例),随机分为观察组29例:接受紫杉醇45mg/m2?d1+奈达铂25?mg/m2?d1化疗,每周一次。对照组29例:接受紫杉醇45mg/m2?d1+顺铂25?mg/m2?d1化疗,每周一次。两组同期行肺部三维适形放疗(GTV:6600cGy/30f/6+w、CTV:6000?cGy?/30F/6+w、PTV:5400?cGy?/30F/6+w)。结果?同步放化疗后评价疗效:观察组:CR1例;PR17例,总有效率(CR+PR)66.7%。对照组:CR0例;PR15例,总有效率(CR+PR)71.4%。χ2=0.02,P>0.05,两组比较差异无统计学意义。白细胞减少;贫血;肝功损害;放射性肺炎及放射性食道炎发生率两组比较差异亦无统计学意义(P>0.05)。肾功损害,恶心;呕吐及体质量下降>10%,发生率观察组明显低于对照组,两组比较差异均有统计学意义(P<0.05)。结论?紫杉醇联合奈达铂与紫杉醇联合顺铂同步放化疗治疗局部晚期非小细胞肺癌疗效确切,但紫杉醇联合奈达铂比紫杉醇联合顺铂患者耐受性更好。
目的?觀察每週小劑量紫杉醇聯閤奈達鉑或順鉑同步放化療治療跼部晚期非小細胞肺癌(NSCLC)的療效及不良反應。方法?58例不能手術Ⅲ期非小細胞肺癌患者(Ⅲa期22例,Ⅲb期36例),隨機分為觀察組29例:接受紫杉醇45mg/m2?d1+奈達鉑25?mg/m2?d1化療,每週一次。對照組29例:接受紫杉醇45mg/m2?d1+順鉑25?mg/m2?d1化療,每週一次。兩組同期行肺部三維適形放療(GTV:6600cGy/30f/6+w、CTV:6000?cGy?/30F/6+w、PTV:5400?cGy?/30F/6+w)。結果?同步放化療後評價療效:觀察組:CR1例;PR17例,總有效率(CR+PR)66.7%。對照組:CR0例;PR15例,總有效率(CR+PR)71.4%。χ2=0.02,P>0.05,兩組比較差異無統計學意義。白細胞減少;貧血;肝功損害;放射性肺炎及放射性食道炎髮生率兩組比較差異亦無統計學意義(P>0.05)。腎功損害,噁心;嘔吐及體質量下降>10%,髮生率觀察組明顯低于對照組,兩組比較差異均有統計學意義(P<0.05)。結論?紫杉醇聯閤奈達鉑與紫杉醇聯閤順鉑同步放化療治療跼部晚期非小細胞肺癌療效確切,但紫杉醇聯閤奈達鉑比紫杉醇聯閤順鉑患者耐受性更好。
목적?관찰매주소제량자삼순연합내체박혹순박동보방화료치료국부만기비소세포폐암(NSCLC)적료효급불량반응。방법?58례불능수술Ⅲ기비소세포폐암환자(Ⅲa기22례,Ⅲb기36례),수궤분위관찰조29례:접수자삼순45mg/m2?d1+내체박25?mg/m2?d1화료,매주일차。대조조29례:접수자삼순45mg/m2?d1+순박25?mg/m2?d1화료,매주일차。량조동기행폐부삼유괄형방료(GTV:6600cGy/30f/6+w、CTV:6000?cGy?/30F/6+w、PTV:5400?cGy?/30F/6+w)。결과?동보방화료후평개료효:관찰조:CR1례;PR17례,총유효솔(CR+PR)66.7%。대조조:CR0례;PR15례,총유효솔(CR+PR)71.4%。χ2=0.02,P>0.05,량조비교차이무통계학의의。백세포감소;빈혈;간공손해;방사성폐염급방사성식도염발생솔량조비교차이역무통계학의의(P>0.05)。신공손해,악심;구토급체질량하강>10%,발생솔관찰조명현저우대조조,량조비교차이균유통계학의의(P<0.05)。결론?자삼순연합내체박여자삼순연합순박동보방화료치료국부만기비소세포폐암료효학절,단자삼순연합내체박비자삼순연합순박환자내수성경호。
Objective?To?observe?efifcacy?and?adverse?reactions?of?the?low-doses?of?paclitaxel?weekly?combined?with?nedaplatin?or?cisplatin?concurrent?with?radiotherapy?and?chemotherapy?for?locally?advanced?non-small?cell?lung?cancer?(NSCLC).?Methods?58?patients?with?inoperable?stage?III?non-small?cell?lung?cancer?(22?cases?with?IIIa?and?stage?36?cases?with?IIIb)?were?randomly?divided?into?observation?group?and?control?group.?In?observation?group?of?29?cases:?paclitaxel?45mg/m2?d1+?nedaplatin?25?mg/m2?d1?once?a?week,?while?in?control?group?of?29?cases:?paclitaxel?45mg/m2?d1?+?cisplatin?25?mg/m2?d1.?All?pationts?in?two?groups?accepted?three-dimensional?conformal?radiotherapy?(GTV:?6600cGy/30f/6+w,?CTV:?6000?cGy/30F/6+w,?PTV:?5400?cGy/30F/6+?w).?Results?In?observation?group?CR?1cases,?PR?17cases,?the?total?response?rate?(CR+PR)?was?66.7%,?and?in?the?control?group:?CR?0?cases;?PR?15?cases,?the?total?response?rate?(CR+PR)?was?71.4%?(P>0.05),?the?difference?was?not?statistically?signiifcant?between?two?groups.?There?was?no?signiifcant?difference?in?two?groups?patients?with?leukopenia,?anemia,?liver?damage,?radiation?pneumonitis?and?radiation?esophagitis,?respectively;?but?renal?damage,?nausea,?vomiting?and?weight?loss?(>10%)?rate?were?signiifcantly?lower?than?the?control?group,?with?statistically?signiifcant?(P<0.05).?Conclusion?The?effective?between?two?regimens?is?the?same?for?locally?advanced?non-small?cell?lung?cancer,?but?paclitaxel?combined?with?nedaplatin?is?better?tolerated?than?paclitaxel?plus?cisplatin?when?synchronous?radiotherapy?.